Pegylated interferon α-2a with or without ribavirin in HCV/HIV coinfection: Partially blinded, randomized multicenter trial

Digestive Diseases and Sciences

Volumn 50, Issue 6, 2005, Pages 1148-1155

  Khalili, Mandana ^a,e   Bernstein, David ^b   Lentz, Ellen ^c   Barylski, Christine ^c   Hoffman Terry, Margaret ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d LEHIGH VALLEY HOSPITAL   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Coinfection; Efficacy; Hepatitis C; PegIFN 2a; Therapy

Indexed keywords

CD4 ANTIGEN; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSCESS; ADULT; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; INSOMNIA; LACTATE BLOOD LEVEL; LYMPHADENOPATHY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NIGHT SWEAT; PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RIGOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; THRUSH; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 20844439557     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2723-5     Document Type: Article

References (32)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860, 1998
2. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kuman PN, Mintz L, Wallach FR, Nemo GJ: Viral Activation Transfusion Study Investigators: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135:17-26, 2001
3. Khalili M, Behm BW: Hepatitis C in the setting of HIV co-infection. Microbes Infect 4:1247-1251, 2002
4. Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P: GERMIVIC Joint Study Group: Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 17:1803-1809, 2003
5. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B: Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33:240-247, 2001
6. Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 34:831-837, 2002
7. Bräu N, Bini EJ, Shahidi A, Aytaman A, Xiao P, Stancic S, Eng R, Brown ST, Paronetto F: Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 97:2071-2078, 2002
8. Klein MB, Lalonde RG, Suissa S: The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33:365-372, 2003
9. Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 31:2679-2682, 1993
10. Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL: Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 6:203-208, 1999
11. Soto B, Sánchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, Rey C, Abad MA, Rodríguez M, Sales Gilabert M, Gonzalez F, Miron P, Caruz A, Relimpio F, Torronteras R, Leal M, Lissen E: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26:1-5, 1997
12. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30:1054-1058, 1999
13. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74-80, 2000
14. Melvin DC, Lee JK, Belsey E, Arnold J, Murphy RL: The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 14:463-465, 2000
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965, 2001
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982, 2002
17. Pérez-Olmeda M, Núñez M, Romero M, Gonzalez J, Castro A, Arribas JR, Pedreira J, Barreiro P, Garcia-Samaniego J, Martin-Carbonero L, Jiménez-Nacher I, Soriano V: Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 17:1023-1028, 2003
18. Nasti G, Di Gennaro G, Tavio M, Cadorin L, Tedeschi RM, Talamini R, Carbone A, Tirelli U: Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 15:1783-1787, 2001
19. Sulkowski M, Felizarta F, Slim J, Dieterich D, Goodman R, Ball L: Final results of daily vs 3-times weekly interferon alpha-2b plus ribavirin for the treatment of hepatitis C infection in HIV-infected persons: a multi-center, randomized open-label study. Presented at 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10-14, 2003, abstract 841
20. Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Golz J, Dupke S, Notheis G, Stein L, Mauss S: German Clinical AIDS Working group (KAAD): Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients. AIDS 16:2083-2085, 2002
21. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeux J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group: Peginterferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Eng J Med 351:438-150, 2004
22. Ferenci P: Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 53:15-18, 2004
23. Lee SS, Heathcote EJ, ReddyKR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Haussinger D, Smith CI, Lin A, Pappas SC: Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 37:500-506, 2002
24. Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357:280-281, 2001
25. Guyader D, Poinsignon Y, Cano Y, Saout L: Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. J Hepatol 37:289-291, 2002
26. Butt AA: Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read 13:344-348, 2003
27. Vogt MW, Hartshorn KL, Furman PA, Chou TC, Fyfe JA, Coleman LA, Crumpacker C, Schooley RT, Hirsch MS: Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235:1376-1379, 1987
28. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D: Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36:97-100, 2003
29. Taylor LE, Costello T, Alt E, Yates G, Tashima K: Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS 16:1700-1701, 2002
30. Gries JM, Torriani FJ, Rodriguez-Torres M, Soriano V, Borucki MJ, Piliero P, Lissen E, Sukowski M, Wang K, Dieterich D, Back D: Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HCV/HIV coinfection: final results of a randomized clinical study. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004, abstract 136LB
31. Perronne C, Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel F, Morand P, Salmon D, Pialoux G, Raguin G, Grillot-Courvalin C, Cacoub P; ANRS HC02-RIBAVIC study group: Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirn vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004, abstract 117LB
32. Chung R, Andersen J, Volberding P, Robbins G, Liu T, Sherman K, Peters M, Koziel M, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A 5071 Study Team: A randomized, controlled trial of PEG-interferon alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV co-infected persons: follow-up results of ACTG A5071. Presented at 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004, abstract 110